← Leaderboards
David B. Solit
Sloan-Kettering Inst Can Research
$21,393,031
Attributed
$28,408,668
Total exposure
15
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.4M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$40,205,856 · 16
By mechanism
P50$15,670,278 · 5
U54$9,924,970 · 1
R01$9,922,036 · 7
P01$4,688,572 · 3
Top collaborators
- Dean F. Bajorin5 shared
- Sarat Chandarlapaty5 shared
- Scott W Lowe5 shared
- Gopa Iyer3 shared
- Randy Yeh2 shared
- Jonathan Eric Rosenberg1 shared
Most similar at Sloan-Kettering Inst Can Research
Same institution · by research overlap
- Neal X Rosen$1,689,713
- Yelena Y Janjigian$1,716,445
- Jason S Lewis$26,024,327
- Sarat Chandarlapaty$10,852,142
- Christine Anne Pratilas$2,591,337
Others in their field
Top investigators on “Mutation”
- Richard A Gibbs · Baylor College Of Medicine$276,143,183
- David Heimbrook · Leidos Biomedical Research, Inc.$175,834,894
- Randall J Bateman · Washington University$154,391,630
- Eric Martin McDade · Washington University$96,219,353
- Stacey Gabriel · Massachusetts Institute Of Technology$95,141,374
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$93,475,056
Research focus
MutationTumorMolecularGenomicsResponseClinical TrialsMalignant NeoplasmsBasePathway InteractionsResistanceGenesNext Generation SequencingSamplingCancer PatientCohortProspectiveMutantFutureCell LineMediatingCell Free DnaMalignant Neoplasm Of Urinary BladderMolecular ProfilingBioinformatics
Grant awards (60)
The Role of EP300 Mutations in Bladder Cancer Pathogenesis and Drug Response$583,973
R01 · FY2025 · CA · contact PI
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma$556,762
R01 · FY2025 · CA
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer$212,659
P50 · FY2025 · CA · contact PI
SPORE in Bladder Cancer$896,275
P50 · FY2024 · CA
HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma$556,681
R01 · FY2024 · CA
Genomics Core$504,114
P01 · FY2024 · CA · contact PI
RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer$323,676
P50 · FY2024 · CA · contact PI
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer$280,975
P50 · FY2024 · CA · contact PI
Genomics Core$514,327
P01 · FY2023 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$402,618
R01 · FY2023 · CA · contact PI
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer$371,700
P50 · FY2023 · CA · contact PI
SPORE in Bladder Cancer$2,138,849
P50 · FY2022 · CA
Genomics Core$514,327
P01 · FY2022 · CA · contact PI
Project 1: Role of the H3K27 demethylase KDM6A in bladder cancer pathogenesis$452,641
P01 · FY2022 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$402,618
R01 · FY2022 · CA · contact PI
Development of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutations$402,618
R01 · FY2022 · CA · contact PI
Project 1: Genomic Predictors of Clinical Outcomes and Response to Targeted Therapy in Advanced Prostate Cancer$362,142
P50 · FY2022 · CA · contact PI
RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer$359,283
P50 · FY2022 · CA · contact PI
Developmental Research Program$79,838
P50 · FY2022 · CA · contact PI
SPORE in Bladder Cancer$2,138,532
P50 · FY2021 · CA
Genomics Core$521,135
P01 · FY2021 · CA · contact PI
Development of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutations$410,835
R01 · FY2021 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$410,835
R01 · FY2021 · CA · contact PI
Project 1: Role of the H3K27 demethylase KDM6A in bladder cancer pathogenesis$391,905
P01 · FY2021 · CA · contact PI
RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer$368,437
P50 · FY2021 · CA · contact PI
Developmental Research Program$156,462
P50 · FY2021 · CA · contact PI
SPORE in Bladder Cancer$2,184,846
P50 · FY2020 · CA
Defining mechanisms of resistance to hormonal therapy in breast cancer$410,835
R01 · FY2020 · CA · contact PI
Development of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutations$410,835
R01 · FY2020 · CA · contact PI
Targeting AKT-Mutant Human Cancers$410,835
R01 · FY2020 · CA · contact PI
Project 1: Role of the H3K27 demethylase KDM6A in bladder cancer pathogenesis$391,906
P01 · FY2020 · CA · contact PI
RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer$373,548
P50 · FY2020 · CA · contact PI
Developmental Research Program$73,073
P50 · FY2020 · CA · contact PI
SPORE in Bladder Cancer$2,138,849
P50 · FY2019 · CA
MSKCC Pilot Center for Precision Disease Modeling$2,038,557
U54 · FY2019 · OD
Genomics Core$541,035
P01 · FY2019 · CA · contact PI
Project 1: Role of the H3K27 demethylase KDM6A in bladder cancer pathogenesis$449,777
P01 · FY2019 · CA · contact PI
Defining mechanisms of resistance to hormonal therapy in breast cancer$410,835
R01 · FY2019 · CA · contact PI
Development of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutations$398,509
R01 · FY2019 · CA · contact PI
RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer$359,282
P50 · FY2019 · CA · contact PI
Developmental Research Program$79,840
P50 · FY2019 · CA · contact PI
SPORE in Bladder Cancer$2,299,837
P50 · FY2018 · CA
MSKCC Pilot Center for Precision Disease Modeling$1,996,560
U54 · FY2018 · OD
Project 1: Role of the H3K27 demethylase KDM6A in bladder cancer pathogenesis$407,405
P01 · FY2018 · CA · contact PI
Development of optimal strategies to inhibit ERK signaling in tumors with RAF and MEK mutations$392,764
R01 · FY2018 · CA · contact PI
RP-1: Defining Predictors of Sensitivity to Cisplatin-Based Chemotherapy in Urothelial Cancer$386,325
P50 · FY2018 · CA · contact PI
Defining the temporal sequence of PI3K pathway mutations in bladder cancer$368,728
R01 · FY2018 · CA · contact PI
Developmental Research Program$85,850
P50 · FY2018 · CA · contact PI
MSKCC Pilot Center for Precision Disease Modeling$1,896,733
U54 · FY2017 · OD
Defining the temporal sequence of PI3K pathway mutations in bladder cancer$368,728
R01 · FY2017 · CA · contact PI
MSKCC Pilot Center for Precision Disease Modeling$1,996,560
U54 · FY2016 · OD
Defining the temporal sequence of PI3K pathway mutations in bladder cancer$368,728
R01 · FY2016 · CA · contact PI
MSKCC Pilot Center for Precision Disease Modeling$1,996,560
U54 · FY2015 · OD
Defining the temporal sequence of PI3K pathway mutations in bladder cancer$368,728
R01 · FY2015 · CA · contact PI
Defining the temporal sequence of PI3K pathway mutations in bladder cancer$368,728
R01 · FY2014 · CA · contact PI
Targeting BRAF and MEK in tumors with BRAF and RAS mutations.$376,384
R01 · FY2012 · CA · contact PI
Targeting BRAF and MEK in tumors with BRAF and RAS mutations.$376,384
R01 · FY2011 · CA · contact PI
Targeting BRAF and MEK in tumors with BRAF and RAS mutations.$388,025
R01 · FY2010 · CA · contact PI
Targeting BRAF and MEK in tumors with BRAF and RAS mutations.$388,025
R01 · FY2009 · CA · contact PI
Targeting BRAF and MEK in tumors with BRAF and RAS mutations.$388,025
R01 · FY2008 · CA · contact PI